Please try another search
The Nomination Committee proposes that the board shall consist of seven members, without deputies.
The Nomination Committee proposes that
The board members
Information on all proposed board members for BioArctic, the Nomination Committee's rationale regarding the proposal for the election of board members and the Nomination Committee's complete proposals to the annual general meeting will be available on the company's website, www.bioarctic.se, in connection with the issuance of the notice to attend the annual general meeting 2024, which is expected to be published around
The Nomination Committee has been appointed according to the principles adopted by the annual general meeting 2023 and consists of Jannis Kitsakis (chairperson), appointed by the Fourth Swedish National Pension Fund (Swedish: Fjärde AP-fonden), Margareta Öhrvall, appointed by Demban AB and
The Nomination Committee of BioArctic AB (publ)
The information was released for public disclosure, through the agency of the contact person below, on
For further information, please contact:
Jannis Kitsakis, chairperson of the Nomination Committee, telephone +46 (0)70 603 80 23
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi ® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioarctic/r/the-nomination-committee-s-proposal-for-the-election-of-board-members-and-chairperson-of-the-board-i,c3962277
The following files are available for download:
https://mb.cision.com/Main/9978/3962277/2735063.pdf | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.